Novartis (NVS) said Friday the US Food and Drug Administration has approved its radioligand therapy Pluvicto for earlier use before chemotherapy in prostate cancer patients.
The new indication allows the use in patients with metastatic castration-resistant prostate cancer who have been treated with an androgen receptor pathway inhibitor therapy and are considered appropriate to delay chemotherapy, Novartis said.
The approval triples the number of patient population eligible to receive Pluvicto, the company said.
Price: 112.29, Change: +0.89, Percent Change: +0.80
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。